Trial Profile

A Phase 2a Study to Evaluate Microglial Activation, Safety, and Clinical Effects of Foralumab Nasal in Patients with Multiple System Atrophy (MSA)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 20 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Foralumab (Primary)
Indications Multiple system atrophy
Focus Therapeutic Use

Most Recent Events

14 Apr 2026 According to a Tiziana Life Sciences media release, the data from the trial has been accepted for presentation at the 7th World Parkinson Congress, 2026.
16 Jan 2026 According to a Tiziana Life Sciences media release, company announced Registered Direct Offering of up to approximately $17.6 Million.The proceeds from this offering enable the company to complete its Phase 2 MSA trial and top line data readouts.
23 Sep 2025 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com